Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

  • End date
    Dec 28, 2021
  • participants needed
  • sponsor
    Masonic Cancer Center, University of Minnesota
Updated on 28 January 2021
ejection fraction
cell transplantation


The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).


Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busulfan, cyclophosphamide, and melphalan are given to destroy the subject's leukemia. As well, these drugs will destroy the subject's own immune system to help ensure the new bone marrow takes and grows after transplantation.

On the day of transplantation, bone marrow or umbilical cord blood from the donor will arrive to the bone marrow transplant unit and be transfused via venous line. These new cells will replace the subject's bone marrow.

Condition Juvenile Myelomonocytic Leukemia
Treatment Stem Cell Transplant, Stem Cell Transplant, Preparative Regimen
Clinical Study IdentifierNCT00167219
SponsorMasonic Cancer Center, University of Minnesota
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age less than or equal to 18 yrs?
Gender: Male or Female
Do you have Juvenile Myelomonocytic Leukemia?
Do you have any of these conditions: Do you have Juvenile Myelomonocytic Leukemia??
Patients must have a diagnosis of JMML and fulfill these minimal criteria (International diagnostic criteria for JMML)
Leukocytosis (> 13,000) with absolute monocytosis (> 1,000)
The presence of immature myeloid cells in the peripheral blood
Less than 30% marrow blasts
Absence of t(9:22) or BCR-ABL transcript
Adequate major organ function including
Cardiac: ejection fraction > 45%
Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)
Karnofsky performance status > 70% or Lansky score > 50%
Creatinine must be < 2 x normal for age
Written informed consent

Exclusion Criteria

Active uncontrolled infection within one week of HCT
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note